Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis
By Giuseppe Lippi, C. Lavie, Fabian Sanchis-Gomar. Progress in cardiovascular diseases, 2020
637 citations recorded by the source corpus.
Coronavirus disease 2019 (COVID-19) is an emerging outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). According to updated statistics released by the World Health Organization (WHO), COVID-19 has already affected over 110,000 people from over 100 countries worldwide, causing N3800 deaths. In up to 15% of infected patients the clinical course of this pathology may be complicated by the onset of a severe form of intestinal pneumonia, which may then progress towards acute respiratory distress syndrome (ARDS) and/or multi organ failure (MOF) and death. People with underlying cardiovascular disease are among the highest risk individuals for severe disease and death. Importantly, among the COVID-19 knowledge gaps are laboratory and diagnostics issues as well as the clinical management of severe and critically ill patients. Since major cardiac complications have been reported to develop in a considerable number of patients with pneumonia, we performed an analysis of the current scientific literature to investigate whether the measurement of cardiac troponin I (cTnI) or cardiac troponin T (cTnT) may help predict clinical severity in patients with COVID-19. An electronic searchwas carried out inMedline (PubMed interface), Scopus and Web of Science, using the keywords “laboratory” OR
Subfields: Cardiology and Cardiovascular Medicine, Infectious Diseases, Oncology
View Paper: https://www.semanticscholar.org/paper/7d12acfc2437f5240d39dc85619e5fc01963cc42
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection (2020, positive): “In these limited case series, troponin elevation was more common in patients with pre-existing cardiovascular disease (CVD) and, when present, was associated with higher rates of adverse outcomes in patients hospitalized with COVID-19 (6).”
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up (2020, background): “Elevated troponin levels are associated with poor outcomes in several studies of COVID-19 (36).”